Rabeprazole
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Healing of erosive or ulcerative GERD | Adults | Monotherapy | FDA Approved |
| Maintenance of healing of erosive or ulcerative GERD | Adults | Monotherapy | FDA Approved |
| Symptomatic GERD | Adults | Monotherapy | FDA Approved |
| Healing of duodenal ulcers | Adults | Monotherapy | FDA Approved |
| H. pylori eradication (duodenal ulcer) | Adults | Triple therapy (with amoxicillin + clarithromycin) | FDA Approved |
| Zollinger-Ellison syndrome and other hypersecretory conditions | Adults | Monotherapy | FDA Approved |
| Symptomatic GERD (adolescents) | ≥12 years | Monotherapy | FDA Approved |
Rabeprazole is a proton pump inhibitor with a distinctive metabolic profile — its primary breakdown occurs through non-enzymatic thioether reduction rather than CYP2C19-mediated pathways. This pharmacological feature makes its acid-suppressive efficacy less variable across different CYP2C19 genotypes compared to omeprazole and lansoprazole, though the clinical significance of this difference remains debated. Its approved indications cover the core spectrum of acid-related disorders, with a notably short 7-day triple therapy regimen for H. pylori eradication.
Stress ulcer prophylaxis in ICU patients — Evidence quality: Moderate. PPIs are widely used for stress ulcer prevention in critically ill patients, though rabeprazole specifically is less commonly chosen in this setting due to the lack of an intravenous formulation.
Functional dyspepsia — Evidence quality: Moderate. Empiric PPI therapy provides modest symptom relief, particularly for epigastric pain syndrome.
NSAID-associated gastroprotection — Evidence quality: Moderate. While not FDA-approved for this indication (unlike lansoprazole), PPIs as a class are recommended by guidelines for gastroprotection in patients at GI risk requiring chronic NSAID use.
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Erosive or ulcerative GERD — healing | 20 mg once daily | 20 mg once daily | 20 mg/day | 4–8 weeks; additional 8 weeks if unhealed Can be taken with or without food |
| Erosive or ulcerative GERD — maintenance of healing | 20 mg once daily | 20 mg once daily | 20 mg/day | Controlled studies up to 12 months |
| Symptomatic GERD — heartburn relief | 20 mg once daily | 20 mg once daily | 20 mg/day | Up to 4 weeks; additional course may be considered if incomplete symptom resolution |
| Duodenal ulcer — healing | 20 mg once daily after morning meal | 20 mg once daily | 20 mg/day | Up to 4 weeks; most patients heal within 4 weeks Must be taken after a meal for this indication |
| H. pylori eradication — triple therapy | 20 mg twice daily | 20 mg twice daily | 40 mg/day | With amoxicillin 1 g BID + clarithromycin 500 mg BID, all with morning and evening meals, for 7 days Shorter 7-day course distinguishes rabeprazole from 10–14-day PPI regimens |
| Zollinger-Ellison syndrome / hypersecretory conditions | 60 mg once daily | Titrate to clinical response | 100 mg QD or 60 mg BID | Adjust to individual patient needs; some patients treated continuously for up to 1 year Some patients may require divided doses; not readily dialysable |
Adolescent Dosing (12 Years and Older)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Symptomatic GERD — ages ≥12 years | 20 mg once daily | 20 mg once daily | 20 mg/day | Up to 8 weeks 20 mg tablet not recommended for patients <12 years (exceeds recommended dose); use sprinkle capsule formulation instead |
Unlike lansoprazole and omeprazole, rabeprazole’s bioavailability is not significantly affected by food or antacid co-administration. For most indications, it can be taken with or without food. The exceptions are duodenal ulcer healing (take after the morning meal) and H. pylori eradication (take with food). This flexibility can improve adherence for patients who find pre-meal dosing difficult. Tablets must be swallowed whole and cannot be crushed, chewed, or split.
Pharmacology
Mechanism of Action
Rabeprazole is a substituted benzimidazole prodrug that irreversibly inhibits the gastric hydrogen-potassium ATPase (H+/K+-ATPase) proton pump at the secretory surface of parietal cells. After systemic absorption, the drug is selectively concentrated in the acidic canalicular space of active parietal cells, where it undergoes rapid acid-catalysed conversion to its active sulfenamide form. Rabeprazole is activated particularly quickly at low pH, with an in vitro activation half-life of 78 seconds at pH 1.2. The sulfenamide covalently binds cysteine residues on the proton pump, producing sustained and dose-dependent suppression of both basal and stimulated acid secretion. The antisecretory effect begins within one hour of dosing and reaches approximately 88% of its maximal effect after the first dose, resulting in faster onset of acid control compared to some other PPIs.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Tmax 2–5 h; absolute bioavailability ~52%; enteric-coated tablet; linear PK over 10–40 mg | Food and antacids do not significantly alter bioavailability, permitting flexible timing with meals for most indications |
| Distribution | 96.3% plasma protein bound; concentrates in parietal cell canaliculi | Extensively protein bound; not removed by haemodialysis |
| Metabolism | Primarily non-enzymatic thioether reduction (major pathway); CYP3A4 (to sulfone) and CYP2C19 (to desmethyl rabeprazole) contribute to enzymatic metabolism; metabolites inactive | Lower dependence on CYP2C19 than omeprazole or lansoprazole; pharmacokinetics less variable across CYP2C19 genotypes; no dose adjustment needed for CYP2C19 poor metabolisers |
| Elimination | t½ 1–2 h; ~90% excreted renally as metabolites; ~10% in faeces; no unchanged drug in urine or faeces; total recovery 99.8% | Short half-life but prolonged acid suppression (>24 h) due to irreversible pump binding; no accumulation with daily dosing; no renal dose adjustment needed |
Side Effects
No individual adverse reaction reached 10% incidence in placebo-controlled adult monotherapy trials of rabeprazole. In the adolescent open-label study (N=111), headache occurred in 9.9% of patients regardless of causality (5.4% treatment-related).
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Pain | 3% (vs 1% placebo) | Non-specific; reported as body pain in clinical trials; usually self-limiting |
| Pharyngitis | 3% (vs 2% placebo) | Upper respiratory tract symptom; marginally above placebo |
| Flatulence | 3% (vs 1% placebo) | May relate to altered gut flora from acid suppression; usually manageable |
| Infection | 2% (vs 1% placebo) | Non-specific infections reported at twice the placebo rate |
| Constipation | 2% (vs 1% placebo) | Increase dietary fibre and fluid; rarely requires discontinuation |
Additional adverse reactions occurring at <2% but with possible causal relationship include headache, abdominal pain, diarrhoea, dry mouth, dizziness, peripheral oedema, hepatic enzyme increase, hepatitis, myalgia, and arthralgia. In adolescents, the most common adverse reactions regardless of causality were headache (9.9%), diarrhoea (4.5%), nausea (4.5%), vomiting (3.6%), and abdominal pain (3.6%).
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Clostridioides difficile-associated diarrhoea | Rare | Days to months | Stool testing; discontinue PPI; targeted antibiotic therapy |
| Acute tubulointerstitial nephritis | Rare | Any point during therapy | Discontinue rabeprazole; evaluate renal function; may require biopsy |
| Hypomagnesaemia | Rare | Usually after ≥3 months; most after ≥1 year | Check magnesium; supplement and consider PPI discontinuation; may cause secondary hypocalcaemia/hypokalaemia |
| Osteoporosis-related fractures | Rare; increased with long-term use | After ≥1 year of high-dose therapy | Use lowest dose/shortest duration; manage per osteoporosis guidelines |
| Severe cutaneous reactions (SJS, TEN) | Very rare; some fatal | Days to weeks | Immediate discontinuation; emergency dermatological care; permanent avoidance |
| Cutaneous and systemic lupus erythematosus | Very rare | Weeks to years | Discontinue PPI; refer to specialist; most resolve within 4–12 weeks |
| Cyanocobalamin (Vitamin B12) deficiency | Rare; with use >3 years | After years of continuous use | Monitor B12 in prolonged users; supplement if deficient |
| Fundic gland polyps | Uncommon; risk increases >1 year | Months to years | Usually asymptomatic; found incidentally on endoscopy; use shortest PPI duration |
| Anaphylaxis / angioedema | Very rare | Any time | Emergency care; permanent discontinuation |
| Blood dyscrasias (agranulocytosis, pancytopenia, thrombocytopenia) | Very rare (post-marketing) | Variable | CBC if unexplained symptoms; discontinue and consult haematology |
| Rhabdomyolysis | Very rare (post-marketing) | Variable | Monitor CK; discontinue; aggressive hydration |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Diarrhoea (triple therapy) | 7–8% | 7-day regimen 8%, 10-day regimen 7%; driven by clarithromycin and amoxicillin |
| Taste perversion (triple therapy) | 6–10% | Metallic taste primarily attributed to clarithromycin; 7-day regimen 6%, 10-day regimen 10% |
Post-marketing reports have identified false positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving PPIs, including rabeprazole. If a positive result occurs, an alternative confirmatory method (e.g., GC-MS) should be used to verify the finding.
Drug Interactions
Rabeprazole undergoes predominantly non-enzymatic metabolism, with minor contributions from CYP3A4 and CYP2C19. Formal interaction studies with warfarin, theophylline, diazepam, and phenytoin showed no clinically significant pharmacokinetic changes. However, its acid-suppressive effects can alter absorption of pH-dependent drugs, and post-marketing reports have identified clinically relevant interactions with warfarin and certain antiretrovirals.
Monitoring
- MagnesiumBaseline and periodically if use >3 months
RoutineSerum magnesium prior to initiation and periodically during prolonged use. Particularly important when co-prescribed with digoxin or diuretics. Also check calcium and potassium, as hypomagnesaemia can cause secondary deficits. - INR (if on warfarin)At initiation and dose changes
RoutinePost-marketing reports of increased INR with concurrent PPI and warfarin. Monitor when starting, adjusting, or stopping rabeprazole. Steady-state interactions have not been formally studied in patients. - Vitamin B12Consider after ≥3 years of use
Trigger-basedMonitor if symptoms of B12 deficiency develop (fatigue, paraesthesias, macrocytic anaemia). Long-term acid suppression impairs B12 absorption from food-protein sources. - Renal FunctionIf signs of nephritis
Trigger-basedMonitor creatinine if unexplained renal decline, malaise, or fever. Acute tubulointerstitial nephritis can occur at any point during PPI therapy. - Bone DensityPer osteoporosis guidelines
Trigger-basedConsider DXA scan for patients on long-term, high-dose PPI therapy with additional fracture risk factors. - Chromogranin AHold PPI ≥14 days before testing
Trigger-basedPPI-induced hypergastrinaemia elevates CgA, causing false positives in neuroendocrine tumour workups. Also hold ≥14 days before secretin stimulation testing. - Digoxin LevelsAt initiation of concurrent use
RoutineRabeprazole increases digoxin AUC by ~19% and Cmax by ~29%. Monitor digoxin concentrations when co-prescribing. - Symptom Response4–8 weeks
RoutineAssess symptom resolution at end of treatment course. Suboptimal response does not exclude gastric malignancy in adults — consider endoscopy, especially in older patients or those with alarm features.
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to rabeprazole, substituted benzimidazoles, or any component of the formulation (reactions include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, urticaria)
- Concomitant use with rilpivirine-containing products
Relative Contraindications (Specialist Input Recommended)
- Severe hepatic impairment — AUC doubled and t½ increased 2–3-fold in mild-moderate cirrhosis; no formal data or dose recommendation for severe impairment; use with caution and close monitoring
- Concurrent high-dose methotrexate — consider temporary withdrawal of rabeprazole to avoid elevated methotrexate levels
- Patients on atazanavir or nelfinavir — avoid combination; consult HIV specialist
Use with Caution
- Long-term use (>1 year) — increased risks of hypomagnesaemia, B12 deficiency, bone fractures, and fundic gland polyps
- Patients at risk for osteoporosis-related fractures
- Hospitalised patients or those on antibiotics — increased C. difficile risk
- Patients on warfarin — monitor INR closely; steady-state interactions not formally studied
- Pregnancy — no adequate human data; animal data suggest possible effects on fetal bone development with other PPIs
The FDA has issued safety communications regarding class-wide PPI risks, including increased risk of C. difficile-associated diarrhoea, bone fractures with long-term and high-dose therapy, hypomagnesaemia (especially after ≥1 year), vitamin B12 deficiency with prolonged use (>3 years), cutaneous and systemic lupus erythematosus, fundic gland polyps, and severe cutaneous adverse reactions (SJS, TEN). Prescribers should use the lowest effective dose for the shortest clinically appropriate duration.
Patient Counselling
Purpose of Therapy
Rabeprazole reduces stomach acid to heal ulcers, protect the stomach lining, and relieve heartburn and acid reflux symptoms. It may be prescribed for a short course (typically 4–8 weeks) or for ongoing maintenance depending on the condition being treated.
How to Take
Swallow the tablet whole — do not crush, chew, or split it. For most indications, rabeprazole can be taken with or without food. For duodenal ulcer healing, take it after the morning meal. For H. pylori treatment, take it with food alongside the prescribed antibiotics. If a dose is missed, take it as soon as remembered unless the next dose is nearly due — do not double up.
Sources
- ACIPHEX (rabeprazole sodium) delayed-release tablets prescribing information. Eisai Inc. Revised 11/2020. DailyMed. dailymed.nlm.nih.govCurrent FDA-approved prescribing information — primary source for all indications, dosing, adverse reactions, drug interactions, and pharmacokinetics.
- ACIPHEX (rabeprazole sodium) prescribing information. FDA label 2023. accessdata.fda.govMost recent FDA label revision confirming all warnings including acute TIN, severe cutaneous reactions, and false positive THC screening.
- ACIPHEX (rabeprazole sodium) prescribing information. FDA label 2014 (includes Sprinkle capsule data). accessdata.fda.govLabel incorporating paediatric sprinkle capsule formulation data for patients aged 1–11 years.
- Dekkers CPM, Beker JA, Thjodleifsson B, et al. Double-blind comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1999;13(1):49-57. doi:10.1046/j.1365-2036.1999.00440.xHead-to-head trial establishing non-inferiority of rabeprazole vs omeprazole for erosive GERD healing.
- Thjodleifsson B, Rindi G, Fiocca R, et al. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. Aliment Pharmacol Ther. 2003;17(3):343-351. doi:10.1046/j.1365-2036.2003.01443.xLong-term maintenance study demonstrating sustained efficacy and safety of rabeprazole over 5 years.
- Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112(2):212-239. doi:10.1038/ajg.2016.563Current ACG guideline informing H. pylori triple therapy regimen selection including PPI-based regimens.
- Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2022;117(1):27-56. doi:10.14309/ajg.0000000000001538GERD management guideline addressing PPI use, step-down strategies, and long-term therapy considerations.
- Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10(6):528-534. doi:10.1007/s11894-008-0098-4Detailed review of PPI activation chemistry; explains rabeprazole’s rapid activation at low pH (78-second half-life at pH 1.2).
- Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazole. Aliment Pharmacol Ther. 1999;13(Suppl 3):27-36. doi:10.1046/j.1365-2036.1999.00022.xKey paper establishing rabeprazole’s predominantly non-enzymatic metabolism and reduced CYP2C19 dependence compared to other PPIs.
- Yasuda S, Ohnishi A, Ogawa T, et al. Pharmacokinetics of rabeprazole following single intravenous and oral administration to healthy subjects. Eur J Clin Pharmacol. 2004;60(5):313-318. doi:10.1007/s00228-004-0774-4Crossover study establishing 51.8% absolute bioavailability and oral elimination half-life of 1.47 h for rabeprazole.
- Adachi K, Katsube T, Kawamura A, et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther. 2000;14(10):1259-1266. doi:10.1046/j.1365-2036.2000.00840.xDemonstrates that rabeprazole’s acid-suppressive effect is less influenced by CYP2C19 genotype than lansoprazole.
- Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther. 1999;13(Suppl 3):18-26. doi:10.1046/j.1365-2036.1999.00021.xReview of rabeprazole’s drug interaction potential confirming minimal CYP-mediated interactions and discussing pH-dependent absorption effects.